The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis
about
Triglyceride-rich lipoproteins as a causal factor for cardiovascular diseaseMass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular diseaseWhy Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches.Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee.A plant-based diet and animal protein: questioning dietary fat and considering animal protein as the main cause of heart disease.Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial resultsA human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.Investigational therapies for hypercholesterolemia.ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure.Assessment by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry of the Effects of Preanalytical Variables on Serum Peptidome Profiles Following Long-Term Sample Storage.Apolipoprotein C-III and High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III in Relation to Diabetes Risk.High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III and Subclinical Atherosclerosis Measures: MESA (The Multi-Ethnic Study of Atherosclerosis).
P2860
Q26745946-C8283E90-3875-457A-9C3E-129F0A5A88CCQ28075372-B1AC4CF6-F0E5-4E45-ADBA-150503F34B2AQ28077776-4A3C032E-8F16-432F-9453-CE37576EF386Q30251632-766696ED-B3A7-444F-BE1E-C72E91E3A1DCQ33572201-A57435D2-6371-4FD8-8237-1F9B82C0EB8FQ33785571-36AD654C-6D06-48C8-8C5F-D39866542551Q34551430-6C02B059-4C73-42C1-BEF9-97476B694A41Q36731776-D16734C0-DEBE-4291-841D-ED68909469B9Q38616263-5CC821FF-EB7C-480B-9C99-C739A441AC7DQ38988355-428A3E28-D4F5-4EC0-9178-23B02FE9BE7BQ39215123-D36F61B8-95E6-43F0-B53B-AF0358CA5880Q39614082-84EF5CD3-B469-4118-92AE-2B672EF813FDQ40214593-7F4DC0A0-A30C-4127-8120-F4881FABE96AQ47281852-FBBE33E8-9A88-4DF5-97DA-9E63E3C76142Q49931504-B6420CD8-B655-4489-8CC1-B4C90ED60646Q50994675-A22E48B6-8114-4485-9FA7-85D54C6452F8Q55056849-3D2C6C48-74C2-4F8C-89C1-F4B67F49D196
P2860
The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The risk of cardiovascular eve ...... matic review and meta-analysis
@ast
The risk of cardiovascular eve ...... matic review and meta-analysis
@en
The risk of cardiovascular eve ...... matic review and meta-analysis
@nl
type
label
The risk of cardiovascular eve ...... matic review and meta-analysis
@ast
The risk of cardiovascular eve ...... matic review and meta-analysis
@en
The risk of cardiovascular eve ...... matic review and meta-analysis
@nl
prefLabel
The risk of cardiovascular eve ...... matic review and meta-analysis
@ast
The risk of cardiovascular eve ...... matic review and meta-analysis
@en
The risk of cardiovascular eve ...... matic review and meta-analysis
@nl
P2093
P31
P3181
P1476
The risk of cardiovascular eve ...... matic review and meta-analysis
@en
P2093
Bernhard Haring
Frank M Sacks
Moritz C Wyler von Ballmoos
P304
P3181
P356
10.1016/J.JACL.2015.05.002
P407
P577
2015-01-01T00:00:00Z